Spyre Therapeutics (SYRE) Treasury Shares (2015 - 2025)
Spyre Therapeutics posted quarterly Treasury Shares of $76932.0 for Q4 2025, down 33.33% year-on-year from $115398.0 in Q4 2024, and down 33.33% on a QoQ basis from $115398.0 in Q4 2024.
Spyre Therapeutics (SYRE) has 10 years of Treasury Shares data on file, last reported at $76932.0 in Q4 2025.
- For the quarter ending Q4 2025, Treasury Shares fell 33.33% year-over-year to $76932.0; the trailing twelve-month figure through Dec 2025 stood at $76932.0 (down 33.33% YoY), and the FY2025 full-year result was $76932.0, down 33.33% from the prior year.
- Treasury Shares for Q4 2025 stood at $76932.0, down from $115398.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $190000.0 in Q4 2021 and bottomed at $5660.0 in Q4 2022.
- The 5-year median for Treasury Shares is $151932.5 (2022), against an average of $132919.4.
- The widest annual swing landed in 2022, when Treasury Shares plunged 97.02%; it then jumped 2618.46% in 2023.
- A 5-year view of Treasury Shares shows it stood at $190000.0 in 2021, then slumped by 97.02% to $5660.0 in 2022, then surged by 2618.46% to $153865.0 in 2023, then dropped by 25.0% to $115398.0 in 2024, then tumbled by 33.33% to $76932.0 in 2025.
- The last three Treasury Shares figures came in at $76932.0 (Q4 2025), $115398.0 (Q4 2024), and $153865.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 76,932.00 |
| Dec 31, 2025 | 76,932.00 |
| Dec 31, 2024 | 115,398.00 |
| Dec 31, 2024 | 115,398.00 |
| Dec 31, 2023 | 153,865.00 |
| Dec 31, 2023 | 153,865.00 |
| Dec 31, 2022 | 5,660.00 |
| Dec 31, 2022 | 5,660.00 |
| Sep 30, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 181,500.00 |
| Jun 30, 2022 | 181,500.00 |
| Mar 31, 2022 | 190,000.00 |
| Mar 31, 2022 | 190,000.00 |
| Dec 31, 2021 | 190,000.00 |
| Dec 31, 2021 | 190,000.00 |
| Dec 31, 2020 | 228,200.00 |
| Dec 31, 2020 | 228,200.00 |
| Dec 31, 2018 | 6,863.00 |
| Dec 31, 2018 | 6,863.00 |
| Dec 31, 2017 | 33,307.00 |
| Dec 31, 2017 | 33,307.00 |
| Dec 31, 2016 | 75,932.00 |
| Dec 31, 2016 | 75,932.00 |
| Dec 31, 2015 | 118,554.00 |
| Dec 31, 2015 | 118,554.00 |